EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB

Reuters

Sep 10

EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB

EUDA Health Holdings Limited, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell (iPSC) solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526730-en) on September 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566049966"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566049966\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566049966?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566049966","market":"us","top_or_hot":-1,"title":"EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EUDA\">EUDA Health Holdings Limited</a>, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell (iPSC) solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/EUDAW\">Euda Health</a> Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526730-en) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-10 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EUDA\">EUDA Health Holdings Limited</a>, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell (iPSC) solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/EUDAW\">Euda Health</a> Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526730-en) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL7mf7Nw:1","article_id":"2566049966","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566049966","pubTimestamp":1757511019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"EUDA Health Holdings Limited, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell  solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and tim","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","EUDA":"EUDA Health Holdings Limited","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4196":"保健护理服务","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"EUDA Health Holdings Ltd.签署收购新加坡生物技术公司GO POSB的意向书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EUDA":0.9,"NDAQ":0.9},"content_text":"EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB\n    \n\nEUDA Health Holdings Limited, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell (iPSC) solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526730-en) on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}